Australia · 
What does GBS Ventures invest in?
GBS Ventures invests most often at Series A and Venture (54% of the rounds on record), in sectors such as Enterprise Software, Marketing and Venture Capital & Private Equity.
GBS Ventures highlights
- 01
40 rounds on record
- 02
Mostly Series A and Venture: 54% of its rounds
- 03
Sole investor in 2 rounds, median $5.0M
- 04
2 exits from the portfolio
What they do
The homepage text does not explicitly describe the organisation's investment activities; the name 'GBS Venture Partners' suggests a venture capital firm, but no supporting text is provided.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- Enterprise SoftwareMarketingVenture Capital & Private Equity
- Based in
- Melbourne, Australia
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first40 appearances
- 2015
1 round
- May
- 2014
5 rounds
- Sept
- Sept
- Apr
- Apr
- Jan
- 2013
1 round
- Jun
- 2012
7 rounds
- Jul
- May
- Apr
- Mar
- Feb
- Jan
- Jan
- 2011
6 rounds
- Aug
- May
- Apr
- Mar
- Mar
- Mar
- 2010
7 rounds
- Aug
- Aug
- Aug
- Jul
- Jul
- Apr
- Mar
- 2009
1 round
- Oct
- 2008
4 rounds
- Dec
- Sept
- Jun
- May
- 2007
3 rounds
- Jul
- Mar
- Feb
- 2006
1 round
- Oct
- 2005
2 rounds
- Oct
- May
- 2004
1 round
- Apr
- 2002
1 round
- Mar
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 3 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
From their own portfolio page (on their website)
15 of 31 we have independently watched raise
AirXpandersCelladonElastagenEndoluminal SciencesHatchtechIvantisMoximed International, IncNeuroVistaNeurovanceNovasysProactaSunshine HeartUptake MedicalViveveXenomeAiMedicsApplied PhysiologyCoDaCogStateDynamic HearingEuthymicsHealthHydrexiaKalobiosMimeticaNeuromonicsPacific Knowledge SystemsPeplinSpinifexVerva Pharmaceuticalsevolution 7
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed2 in all
Spinifex PharmaceuticalsBought by Novartis$200MJun 2015
KaloBios PharmaceuticalsListedUndisclosedJan 2013
An exit counts when it came after the firm's first round in the company. From historical deal records.